A new one study Multinational reveals that magnetic resonance imaging is a cost-effective alternative for diagnosing and treating disease steatotic liver disease associated with metabolic dysfunction (SLD). The study, conducted in four countries, focused on the use of LiverMultiScan, a multiparametric magnetic resonance imaging tool, which offers benefits for both patients and healthcare professionals.
Reduction of costs and invasive procedures
LiverMultiScan has proven to be more cost-effective than liver biopsies. The study showed an improvement in diagnostic rates with 10% compared to traditional methods. Furthermore, the need for specialist consultations, visits to general practitioners, and ultrasound procedures was reduced.
Another crucial finding is that 50% avoids unnecessary biopsies, representing a safer and less painful option for patients. Multiparametric MRI also facilitates more accurate diagnosis, allowing for more timely treatment.
Global impact and benefits for the health system
The study underscores the high cost associated with managing chronic liver disease, especially MASLD, which affects 30% of the population in North America and Europe. Implementation of technologies like LiverMultiScan could significantly reduce medical costs, estimated at 103 billion annually in the US alone.
According to Dr. Rajarshi Banerjee, CEO of Perspectum, this diagnostic breakthrough can improve disease management without increasing the burden on healthcare services. Furthermore, noninvasive diagnostic innovations will help improve the efficiency of the healthcare system.
This project has been funded by the European Union's Horizon 2020 programme.
